← Eichor
Study identifier: NCT07015073 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparative of Sequential Application of Pulsed Dye Laser and Potassium-titanyl-phosphate Laser Treatment for Capillary Malformations Versus Single Application

Condition: Port-Wine Stains (Capillary Malformations)  ·  Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This prospective, non-randomized study aims to evaluate the efficacy and tolerability of treating port-wine stains (capillary malformations) using pulsed dye laser (PDL), potassium titanyl phosphate (KTP) laser, or a sequential combination of both. Each participant will receive all three treatments on different areas of the lesion. The primary outcome is improvement measured using the Investigator Global Assessment (IGA) scale. Secondary outcomes include pain (VAS), local adverse events, and patient satisfaction.

This description comes directly from the study's public registry record.

Talk to the study team

Jorge Naharro-Rodriguez, M.D.  ·  +34 91 336 80 00  ·  jorgenrmed@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ramon y Cajal University HospitalMadrid, Spain, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07015073